AVP-786 for the treatment of agitation in dementia of the Alzheimer’s type
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Agitation is common and distressing in patients with Alzheimer-type dementia, but safe, effective treatments remain elusive. Psychological treatments are first-line options, but they have limited efficacy. Off-label psychotropic medications are frequently used, but they also have limited effectiveness, and their use may have harmful side effects, including death. Areas covered: This review discusses the history leading to the conception of AVP-786 (deuterated (d6)-dextromethorphan/quinidine), its pharmacokinetic and pharmacodynamic profiles and safety issues, together with an overview of recent clinical trials. Data were found in the medical literature, in US and EU clinical trial registries and in information provided by the manufacturer. Expert opinion: AVP-786 is one of six investigational compounds in recent phase III clinical development for agitation in Alzheimer disease (AD). Quinidine and deuteration appear to prolong dextromethorphan's plasma half-life and facilitate brain penetration. The FDA granted fast-track designation to AVP-786 and allowed use of data generated on dextromethorphan-quinidine (AVP-923, Nuedexta®) for regulatory filings. AVP-923 reduced agitation in AD and was well tolerated in a phase II RCT that included more than 200 patients. A phase III clinical development program of AVP-786 for AD agitation was recently initiated. This program is expected to start generating results in July 2018.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Burns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859
Kales, H. C., Gitlin, L. N., Lyketsos, C. G., & Dementia, T. D. E. P. O. T. A. A. M. O. T. N. S. O. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12730 · Cited by 575
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · cited 2×
“A significant reduction in agitation was recently reported for a phase III RCT of the SSRI antidepressant citalopram at 30 mg daily, but cognitive and cardiac adverse effects occurred at that dose [112].”
BackgroundNonpharmacologic Management of Behavioral Symptoms in Dementia
Gitlin, L. N., Kales, H. C., & Lyketsos, C. G. (2012) · JAMA · doi:10.1001/jama.2012.36918 · Cited by 495
The Burden of Health Care Costs for Patients With Dementia in the Last 5 Years of Life
Kelley, A. S., McGarry, K., Gorges, R., & Skinner, J. S. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0381 · Cited by 373 · cited 1×
“ring healthcare costs substantially larger than those for other diseases [1,3].”
BackgroundCummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., et al. (2015) · JAMA · doi:10.1001/jama.2015.10214 · Cited by 209
Ballard, C., Orrell, M., YongZhong, S., Moniz-Cook, E., Stafford, J., Whittaker, R., Woods, B., Corbett, A., Garrod, L., Khan, Z., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15010130 · Cited by 142
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089985 · Cited by 99
Cited by
Applications of Deuterium in Medicinal Chemistry
Pirali, T., Serafini, M., Cargnin, S., & Genazzani, A. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01808 · Cited by 855
Recent Developments for the Deuterium and Tritium Labeling of Organic Molecules
Kopf, S., Bourriquen, F., Li, W., Neumann, H., Junge, K., & Beller, M. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00795 · Cited by 649
Deuterium in drug discovery: progress, opportunities and challenges
Di Martino, R. M. C., Maxwell, B. D., & Pirali, T. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00703-8 · Cited by 539
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Lanctôt, K. L., Amatniek, J., Ancoli‐Israel, S., Arnold, S. E., Ballard, C., Cohen‐Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.001 · Cited by 395
“A combination of dextromethorphan hydrobromide and quinidine sulfate, which is approved for the treatment of pseudobulbar affect in amyotrophic lateral sclerosis, is being investigated as a treatment for agitation in AD [70].”
BackgroundNew therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105
“It is now in clinical trials for the treatment of agitation in patients with AD [88].”
Background
Metadata
- Authors
- Garay, R. P., & Grossberg, G. T.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2016-12-11
- Volume
- 26
- Issue
- 1
- Pages
- 121-132
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2565303693
- Cited by
- 58
- References
- 10
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AVP-786 for the treatment of agitation in dementia of the Alzheimer’s type. https://app.cochat.ai/papers/10.1080/13543784.2017.1267726
- The paper
- Garay, R. P., & Grossberg, G. T. (2017). AVP-786 for the treatment of agitation in dementia of the Alzheimer’s type. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2017.1267726
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.